Research progress on risk factors of urogenic sepsis after minimally invasive intracorporeal lithotripsy
Zhang Dawei1,2, Yang Cheng3, Tan Yangyang1, Li Yuxiang1, Yuan Yacheng1, Qiu Xiaolong1, Luo Hengfeng1, Li Ruijie1, Yang Xukai2,*
1The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou 730051, China; 2Department of General Surgery, No.940 Hospital of Joint Logistcs Support Force, Lanzhou 730050, China; 3Graduate School of Air Force Military Medical University, Xi’an 710032, China
Abstract：Minimally invasive intracorporeal lithotripsy is now the first choice for the treatment of upper urinary tract calculi. Despite its safety, effectiveness and the high rate of stone removal, there are still complications after surgery, among which urinary sepsis is the most serious one due to its low incidence, rapid progression and high mortality, thus attracting the attention of clinicians. Many factors in the perioperative period will increase the risk of postoperative urinary sepsis. Through reviewing the literature, a review is made on the pathogenesis, risk factors and prevention of urinary sepsis caused by minimally invasive intracorporeal lithotripsy so as to provide a reference for clinical work.
张大伟, 杨成, 谭扬扬, 李宇翔, 袁亚成, 邱小龙, 罗恒丰, 李瑞杰, 杨旭凯. 微创腔内碎石术后并发尿源性脓毒血症危险因素研究进展[J]. 微创泌尿外科杂志, 2022, 11(5): 347-351.
Zhang Dawei, Yang Cheng, Tan Yangyang, Li Yuxiang, Yuan Yacheng, Qiu Xiaolong, Luo Hengfeng, Li Ruijie, Yang Xukai. Research progress on risk factors of urogenic sepsis after minimally invasive intracorporeal lithotripsy. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2022, 11(5): 347-351.
[1] Dreger NM, Degener S, Ahmad-Nejad P, et al.Urosepsis--etiology, diagnosis, and treatment[J]. Dtsch Arztebl Int, 2015,112(49):837-847. [2] Kallidonis P, Panagopoulos V, Kyriazis I, et al.Complications of percutaneous nephrolithotomy: classification, management, and prevention[J]. Curr Opin Urol, 2016,26(1):88-94. [3] 李恭会,王正会.腔内碎石术后尿源性脓毒血症研究进展[J]. 浙江医学, 2020, 42(24): 2605-2608. [4] Rhodes A, Evans LE, Alhazzani W, et al.Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017,43(3): 304-377. [5] Shankar-Hari M, Phillips GS, Levy ML, et al.Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 775-787. [6] Wagenlehner FM, Tandogdu Z, Bjerklund JT.An update on classification and management of urosepsis[J]. Curr Opin Urol, 2017,27(2):133-137. [7] Venet F, Monneret G.Advances in the understanding and treatment of sepsis-induced immunosuppression[J]. Nat Rev Nephrol, 2018,14(2):121-137. [8] Bonkat G, Cai T, Veeratterapillay R, et al.Management of urosepsis in 2018[J]. Eur Urol Focus, 2019,5(1):5-9. [9] Kakihana Y, Ito T, Nakahara M, et al.Sepsis-induced myocardial dysfunction: pathophysiology and management[J]. J Intensive Care, 2016,4:22. [10] 申吉泓, 张白羽. 泌尿外科医生必须高度重视的尿源性脓毒血症[J]. 现代泌尿外科杂志, 2014,19(4):219-221. [11] 伍宏亮. 输尿管镜钬激光碎石术后尿源性脓毒血症的危险因素分析[J].中华全科医学,2016,14(12):2031-2033. [12] Fukunaga A, Nishihara T, Kono Y, et al.Risk factors for mortalityin patients with urosepsis[J]. Hinyokika Kiyo, 2017, 63(5): 195-199. [13] 谢圣陶,陈广瑜,汤尧,等.尿源性脓毒血症的相关因素分析及早期诊断和治疗[J].国际泌尿系统杂志,2017,37(4):546-549. [14] Kumar S, Bag S, Ganesamoni R, et al.Risk factors for urosepsis following percutaneous nephrolithotomy: role of 1 week of nitrofurantoin in reducing the risk of urosepsis[J]. Urol Res, 2012,40:79-86. [15] 玉苏甫·艾比布力,哈木拉提·吐送,王峰,等.输尿管软镜碎石术并发尿源性脓毒血症的危险因素分析[J].中华腔镜泌尿外科杂志(电子版),2017,11(1):49-53. [16] Ergin G, Kirac M, Kopru B, et al.Flexible ureterorenoscopy versus mini-percutaneous nephrolithotomy for the treatment of renal Stones[J]. Urol J, 2018,15(6):313-317. [17] Ferreira TC, Dutra MG, Vicentini FC, et al.Impact of obesity on outcomes of supine percutaneous nephrolithotomy[J]. J Endourol, 2020,34(12): 1219-1222. [18] Kamei J, Yamamoto S.Complicated urinary tract infections with diabetes mellitus[J]. J Infect Chemother, 2021,27(8):1131-1136. [19] 曾国华,李佳胜,吴文起,等.逆行软性输尿管镜下钬激光碎石术治疗肾结石的有效性与安全性分析[J].中华泌尿外科杂志,2015,36(6):401-404. [20] Heyns CF.Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder[J]. World J Urol,2012,30(1): 77-83. [21] 钱永,杜永强,单卫民,等.经皮肾镜、输尿管镜碎石术后尿源性脓毒血症发生的相关危险因素分析[J].国际泌尿系统杂志,2020,40(4):646-649. [22] 邹雄,陈悟文,廖国涛,等.输尿管软镜碎石术后尿源性脓毒血症的防治[J].中华腔镜泌尿外科杂志(电子版),2020,14(3):238-240. [23] McAleer IM, Kaplan GW, Bradley JS, et al. Endotoxin content in renal calculi[J]. J Urol, 2003,169(5):1813-814. [24] Koras O, Bozkurt IH, Yonguc T, et al.Risk factors for postoperative infectious complications following percutaneous nephrolithotomy: a prospective clinical study[J]. Urolithiasis, 2015,43(1):55-60. [25] 张正龙,刘修恒,罗洪波,等.PCNL术后尿源性脓毒血症的危险因素及治疗研究[J].国际泌尿系统杂志,2017,37(2):206-209. [26] 毛俊彪,袁平成,桂定文,等.输尿管软镜钬激光碎石术后尿源性脓毒血症5例分析及对策[J].微创泌尿外科杂志,2015,4(4):221-223. [27] 黄挺. 输尿管软镜碎石术中肾盂高压并发症的研究进展[J].国际泌尿系统杂志,2020,40(5):910-912. [28] Flannigan R, Choy WH, Chew B, et al.Renal struvite stones--pathogenesis, microbiology, and management strategies[J]. Nat Rev Urol, 2014,11(6):333-341. [29] Schaeffer EM.Re: Pre- and post-operative predictors of infection-related complications in patients undergoing percutaneous nephrolithotomy[J]. J Urol, 2018,199(6):1376-1377. [30] 杜建辉,向芹,杨振琪,等.经皮肾镜碎石术后患者尿源性脓毒血症的影响因素分析[J].国际泌尿系统杂志,2021,41(1):49-52. [31] Bag S, Kumar S, Taneja N, et al.One week of nitrofurantoin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study[J]. Urology, 2011,77(1):45-49. [32] Ao P, Shu L, Zhuo D, et al.Risk factors associated with systemic inflammatory response syndrome after flexible ueteroscopic lithotripsy based on enhanced recovery after surgery[J]. Zhonghua Yi Xue Za Zhi, 2019,99(10):758-763. [33] 葛启斌,潘昊,陈慧英,等.肾穿刺造瘘预防输尿管软镜钬激光碎石术后感染的研究[J].中华医院感染学杂志,2016,26(3):633-635. [34] 葛广成,李中兴,冯瑞,等.经皮肾镜取石术后尿源性脓毒血症的诊治[J].国际泌尿系统杂志,2014,34(1):31-32. [35] Taylor C, Thompson K, Finfer S, et al.Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST[J]. Lancet Respir Med, 2016,4(10):818-825. [36] 唐伟. 2017年欧洲泌尿外科学会尿脓毒血症诊疗指南解读[J].重庆医科大学学报,2018,43(4):480-481. [37] 李为兵. 经皮肾镜碎石取石术并发症及其防治[J].中华泌尿外科杂志,2012(1):10-12. [38] 蒲倩,修光辉,孙洁,等.间充质干细胞外泌体在脓毒症多器官功能障碍中作用的研究进展[J].中华危重病急救医学,2021,33(6):757-760. [39] 李成. 乌司他丁联合连续性血液净化对重症脓毒血症患者D-二聚体和降钙素原的影响[J].临床合理用药杂志,2021,14(8):28-30. [40] Jarczak D, Kluge S, Nierhaus A.Use of intravenous immunoglobulins in sepsis therapy-a clinical view[J]. Int J Mol Sci, 2020,21(15):5543.
